CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

Researchers randomized 188 patients with type 2 diabetes and hemoglobin A 1c levels higher than 8%, despite therapy with 2 oral drugs, to receive either a third oral medication or a 70/30 insulin ...

Abbott and MSD Pharmaceuticals have partnered to distribute oral anti-diabetic medicines in India. Abbott will distribute MSD's sitagliptin, its combination sitagliptin/metformin, and the ...

Abbott and MSD Pharmaceuticals announced a partnership to distribute oral anti-diabetic medicines, specifically sitagliptin, ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

A full description of participant characteristics and medications used at ... trial investigating the use of oral semaglutide in persons with type 2 diabetes and high cardiovascular risk, in ...

Abbott & MSD ink strategic pact to distribute innovative oral anti-diabetic medicines in India: Our Bureau, Bengaluru Thursday, June 19, 2025, 12:30 Hrs [IST] Abbott and MSD Pharm ...

Abbott and MSD Pharmaceuticals announced a distribution pact for oral anti-diabetic medicines like Januvia, Janumet, and ...

Abbott partners with MSD to distribute leading diabetes medications in India, enhancing patient access and care.